We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI-Enabled Biochip Detects microRNA Biomarkers in Minutes

By LabMedica International staff writers
Posted on 17 Apr 2026

Detecting circulating microRNAs, small RNA molecules linked to diverse diseases, is technically challenging because they are scarce and often share similar sequences. More...

Conventional workflows based on PCR can take hours and demand complex preparation, limiting throughput in clinical laboratories. Faster, multiplexed assays could strengthen biomarker measurement for oncology and other specialties. A new study shows that an artificial intelligence–enabled nanophotonic biochip can identify multiple microRNA targets in about 20 minutes.

Researchers at Nanyang Technological University (NTU Singapore), developed a biosensing platform that marries a specially designed nanophotonic chip with AI-automated image analysis. With a small drop of blood loaded into the chip, the system images thousands of microRNA signals in a single snapshot, enabling rapid, multiplex readouts. The work is published in Advanced Materials.

The platform’s core is a light-trapping “nanocavity,” a structure hundreds of times smaller than a human hair that reflects and amplifies fluorescence when a target microRNA binds to its matching probe. An automated imaging workflow captures signals in one shot. A deep-learning model known as Mask R-CNN then identifies and classifies fluorescent events by microRNA type, removing the need for manual counting and reducing operator error.

In testing, the system measured three microRNAs associated with non-small cell lung cancer—miR-191, miR-25, and miR-130a—from human lung cancer cell extracts without nucleic acid amplification or complex sample preparation. It also performed well when synthetic microRNAs were spiked into biological extracts, indicating robustness in more realistic matrices. Compared with polymerase chain reaction, the approach shortened analysis from hours to approximately 20 minutes.

According to the team, the platform detected targets at extremely low concentrations, down to a few molecules in a sample, and achieved more than 99% accuracy in identifying microRNAs across different test channels. The researchers built a compact prototype featuring a color camera to image the chip and a mobile phone application that uses AI algorithms to analyze microRNA signals and return rapid results.

“Our goal was to create a platform that can directly measure multiple microRNAs with very high sensitivity and at high throughput. By combining nanophotonic signal enhancement with AI-based image analysis, we were able to detect tiny amounts of RNA molecules across thousands of nanocavities within minutes,” said Bowen Fu, Ph.D. student at NTU’s Institute for Digital Molecular Analytics and Science (IDMxS).

"Our successful tests with lung cancer cells show that, with the right probes targeting different biomarkers, this technology could potentially be adapted for many other cancers and diseases, including cardiovascular and viral diseases," said NTU Associate Professor Chen Yu-Cheng, who led the study at the School of Electrical and Electronic Engineering.

Related Links
NTU Singapore


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Automated Immunoassay Analyzer
SuperFlex™
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.